Gitnux/Report 2026

Alzheimers Biologics Industry Statistics

The 2025 global Alzheimer’s disease treatment market reached $6.94 billion, explore the alzheimers biologics figures behind companies, growth and trends in 2026.
13Statistics
20Sources
2Sections
1Visuals
13mRead
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 44 days

01 Industry overview

The alzheimers biologics industry at a glance

The Alzheimer’s biologics industry is expanding clinically: 54 biological therapies were in development across 192 Alzheimer’s trials as of January 1, 2026, while commercial adoption remains concentrated in anti-amyloid antibodies.

54[1]
Biologic therapies in pipeline, 2026
192[1]
Active Alzheimer’s trials, 2026
$177.7M[4]
Biogen Leqembi revenue share, 2025
$28,270[5]
Annual Leqembi IV list price, 2026
Market share & regions
Commercial biologics activity is concentrated in the United States and other markets where anti-amyloid antibodies are approved and reimbursed. In the 2026 development pipeline, 12% of Phase 3 trials were conducted only in North America, 24% only outside North America, and 63% in both regions.[1]
Segmentation
The 2026 pipeline contained 158 drugs across 192 trials. Biological therapies represented 54 of 116 disease-targeted therapies, or 47%; among disease-targeted therapies, 25 agents targeted amyloid-beta-related processes and 15 targeted tau-related processes.[1]
Key players & concentration
The commercial market is concentrated around Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla, the two leading approved disease-modifying anti-amyloid biologics. In clinical development, biopharmaceutical companies sponsored 72% of Phase 3 Alzheimer’s trials and 61% of Phase 3 drugs in the 2026 pipeline.[1][6]
Pricing
Leqembi’s July 2026 U.S. list-price example was $28,270.32 per year for a 165-pound patient receiving twice-monthly IV treatment, excluding diagnostic, monitoring, and administration costs. Its weekly subcutaneous maintenance presentation was listed at $20,020 annually after the initial 18-month dosing period.[5]
Trends, drivers & challenges
Pipeline activity is broadening beyond amyloid: the 2026 pipeline included 28 agents targeting inflammation or immune processes, 25 targeting amyloid-beta-related pathology, and 15 targeting tau. Major constraints include safety monitoring, high development failure rates, and limited real-world uptake; the review reported no new Alzheimer’s drug approvals since 2023.[1][7]
Consumer behavior & competition
Patient access is concentrated in early Alzheimer’s disease because Leqembi is indicated for mild cognitive impairment or mild dementia stages and requires confirmed amyloid pathology plus MRI monitoring. Competition is primarily between Leqembi, administered on a weight-based schedule, and Kisunla, an anti-amyloid antibody approved by the FDA on July 2, 2024.[8][6]
Regulation
U.S. Medicare coverage for FDA-approved monoclonal antibodies directed against amyloid is provided under Coverage with Evidence Development for patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Leqembi labeling requires confirmation of amyloid pathology, a recent baseline MRI, and additional MRIs during treatment to monitor for amyloid-related imaging abnormalities.[9][8]
Latest news
On July 13, 2026, the FDA approved the first at-home starting dose for an Alzheimer’s disease treatment, expanding Leqembi’s administration options beyond infusion-center initiation. The 2026 pipeline review also identified 59 new Alzheimer’s trials compared with the January 1, 2025 index date.[6][1]

02 Ranking

Top 10 Companies in the Alzheimers Biologics Industry

The leading companies in the alzheimers biologics industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

Eli Lilly and Company stands out for early Alzheimer’s anti-amyloid antibody work because it markets Kisunla for early Alzheimer’s disease, while Eisai focuses on Leqembi since it leads global Leqembi development and regulatory submissions with Biogen.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in anti-amyloid antibodies

    Eli Lilly and Company

    US

    Ranked #1 · 9.9 · Anti-amyloid antibodies

    Why we picked it: Kisunla targets early Alzheimer’s via an approved anti-amyloid antibody, while Lilly also reports an operating margin of 40.4%.

  2. Leader in alzheimer’s biologic development partnerships

    Eisai

    JP

    Ranked #2 · 9.1 · Alzheimer’s biologic development partnerships

    Why we picked it: Eisai leads Leqembi development and regulatory submissions with Biogen and allocates R&D equal to 23% of revenue.

  3. Leader in alzheimer’s biologic pipeline

    Roche

    CH

    Ranked #3 · 9.0 · Alzheimer’s biologic pipeline

    Why we picked it: Roche’s Alzheimer’s portfolio includes investigational trontinemab and other biologic candidates, with R&D at 19.8% of revenue.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the alzheimers biologics industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Anti-amyloid antibodies · US

9.9
2

Eisai

Alzheimer’s biologic development partnerships · JP

9.1
3

Roche

Alzheimer’s biologic pipeline · CH

9.0
4

Johnson & Johnson

Tau immunotherapies · US

8.6
5

Biogen

Alzheimer’s biologic manufacturing · US

8.5
6

Bristol Myers Squibb

Tau antibody programs for Alzheimer’s · US

8.4
7

Denali Therapeutics

Brain-shuttle antibodies for Alzheimer’s · US

8.2
8

Alzinova

Oligomer-targeting Alzheimer’s vaccines and antibodies · SE

7.6
9

AC Immune

Alzheimer’s vaccines and anti-tau immunotherapies · CH

7.5
10

Vaxxinity

Active immunotherapy vaccines for Alzheimer’s · US

7.1

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 19). Top 10 companies in the alzheimers biologics industry. In Alzheimers Biologics Industry Statistics. Gitnux. https://gitnux.org/alzheimers-biologics-industry-statistics/#top-companies

report visual · Comparison

Global Alzheimer's disease drug development pipeline composition by therapy type

Small-molecule disease-targeting therapies holds the largest share at 39%.

Small-molecule disease-targeting therapies39%
Biologic disease-targeting therapies34%
Cognition-enhancing symptom-targeted therapies18%
Neuropsychiatric symptom-targeted therapies10%
source-verifiedalz-journals.onlinelibrary.wiley.com

04 Statistics

Technology

The pipeline contains 54 biological disease-targeted therapies across 192 Alzheimer’s trials on January 1, 2026, with Phase 3 at 11 among 21.

R&D, patents and design rights in the alzheimers biologics industry

  • 54 biological disease-targeted therapies were in 192 Alzheimer’s disease clinical trials globally on January 1, 2026, classified using the Common Alzheimer’s Disease Research Ontology; this is the closest available category-level proxy for Alzheimer’s biologics.[1]
  • 22 biological disease-targeted therapies were in Phase 2 Alzheimer’s disease trials globally on January 1, 2025, among 60 Phase 2 disease-targeted therapies.[1]
  • 11 biological disease-targeted therapies were in Phase 3 Alzheimer’s disease trials globally on January 1, 2026, among 21 Phase 3 disease-targeted therapies.[1]
  • 42 biological disease-targeted therapies were in 182 Alzheimer’s disease clinical trials globally on January 1, 2025, representing 41% of all disease-targeted therapies in the pipeline.[1]

05 Statistics

Market Intelligence

Market context spans USD 4.05 billion in 2022 and USD 6.94 billion in 2025, while a 2030 projection reaches USD 9.51 billion with a 6.6% CAGR.

Market size, volume and shipments in the alzheimers biologics industry

  • USD 4.05 billion was the estimated 2022 global Alzheimer’s therapeutics market size; the broader category includes biologics alongside small-molecule and symptomatic treatments, measured as revenue.[2]
  • USD 6.94 billion was the estimated 2025 global Alzheimer’s disease treatment market size; the category includes immunoglobulins and monoclonal antibodies as well as non-biologic treatments, measured as revenue.[3]

Forecast growth and shipments in the alzheimers biologics industry

  • USD 9.51 billion is the projected 2030 global Alzheimer’s disease treatment market size, implying a 6.6% CAGR during 2025–2030; the category includes monoclonal antibodies and other treatments.[3]
  • A 19.99% CAGR is forecast for the global Alzheimer’s therapeutics market from 2023 through 2030; the market definition includes biologics within the broader therapeutics category.[2]
  • A 6.6% CAGR is forecast for the global Alzheimer’s disease treatment market from 2025 through 2030, driven partly by monoclonal-antibody adoption; the category is broader than biologics alone.[3]
  • USD 15.19 billion is the projected 2030 global Alzheimer’s therapeutics market size, with a 19.99% CAGR from 2023 to 2030; the category includes biologics and non-biologic Alzheimer’s treatments.[2]

Company counts and size structure in the alzheimers biologics industry

  • 42 biological therapies represented 41% of the 102 disease-targeting therapies in the 2025 Alzheimer’s drug-development pipeline, which contained 138 drugs across 182 trials.[1]
  • 23 biologic disease-targeting therapies were among 84 drugs in Phase 2 Alzheimer’s trials on January 1, 2026, representing 38% of Phase 2 disease-targeting therapies.[1]
  • 24 biologic disease-targeting therapies were among 45 drugs in Phase 1 Alzheimer’s trials on January 1, 2026, representing 62% of Phase 1 disease-targeting therapies.[1]

Key questions about the alzheimers biologics industry

How big is the Alzheimer’s therapeutics market used for biologics context in 2022 and 2025?
The global Alzheimer’s therapeutics market size was USD 4.05 billion in 2022 and USD 6.94 billion in 2025, measured as revenue for categories that include biologics alongside small-molecule and symptomatic treatments.
What growth rates are forecast for Alzheimer’s treatment markets through 2030?
The Alzheimer’s therapeutics market is forecast at a 19.99% CAGR from 2023 through 2030, while the broader Alzheimer’s disease treatment market is forecast at a 6.6% CAGR from 2025 through 2030.
Which companies lead the alzheimers biologics industry?
Eli Lilly and Company stands out for early Alzheimer’s anti-amyloid antibody work because it markets Kisunla for early Alzheimer’s disease, while Eisai focuses on Leqembi since it leads global Leqembi development and regulatory submissions with Biogen.
How is the Alzheimer’s biologics pipeline trending beyond anti-amyloid in 2026?
The 2026 pipeline included 28 agents targeting inflammation or immune processes, alongside 25 targeting amyloid-beta-related pathology and 15 targeting tau.
Where does clinical development volume sit geographically in the 2026 Phase 3 pipeline?
In the 2026 development pipeline, 12% of Phase 3 trials were conducted only in North America, 24% only outside North America, and 63% in both regions.
What constraints and selection requirements shape patient access for approved biologics?
Access is concentrated in early Alzheimer’s because Leqembi requires confirmed amyloid pathology plus MRI monitoring, and Medicare coverage is provided under Coverage with Evidence Development for patients with mild cognitive impairment or mild Alzheimer’s dementia.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 19). Alzheimers Biologics Industry Statistics. Gitnux. https://gitnux.org/alzheimers-biologics-industry-statistics
MLA
Samuel Norberg. "Alzheimers Biologics Industry Statistics." Gitnux, 19 Nov 2026, https://gitnux.org/alzheimers-biologics-industry-statistics.
Chicago
Samuel Norberg. 2026. "Alzheimers Biologics Industry Statistics." Gitnux. https://gitnux.org/alzheimers-biologics-industry-statistics.